Carolyn Nelson, MD
Endocrinology, Diabetes & Metabolism · Savannah, GANPI 1285021626
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Cequr Corporation at 46.6% of the total. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 463 payments — averaging $53.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cequr Corporation$11K
- Tandem Diabetes Care, Inc.$2K
- Amgen$1K
- Insulet Corporation$1K
- Novo Nordisk$1K
- Lilly USA, LLC$732
- plus $7K from 38 others
What the payments were for
- Speaking & faculty fees$10,62543%
- Travel & lodging$1,3556%
- Food & beverage$12,04249%
- Education$1721%
- Gifts$1781%
- Other$2601%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$11,456
- t:slim X2 Insulin Pump with Control-IQ$1,815
- iLet Bionic Pancreas$1,058
- Omnipod$557
- Korlym$355
- TEPEZZA$334
- EVENITY$241
- Tymlos$229
- FREESTYLE COPILOT$220
- Wegovy$125
- iLet Insulin Infusion Kit Inset$115
- iLet Insulin Infusion Kit Contact Detach$115
- NEXLIZET$112
- NEXLETOL$112
- Kerendia$112
- Prolia$105
How this compares
$24,632 in reported general payments places this provider in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 380 | $649,061 |
| TrulicityDulaglutide | 139 | $253,352 |
| MounjaroTirzepatide | 147 | $207,746 |
| FarxigaDapagliflozin Propanediol | 144 | $160,494 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 78 | $114,298 |
| JardianceEmpagliflozin | 85 | $101,624 |
| Tresiba Flextouch U-100Insulin Degludec | 99 | $77,389 |
| KerendiaFinerenone | 45 | $69,109 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $42,689 |
| Tresiba Flextouch U-200Insulin Degludec | 30 | $38,500 |
| Novolog FlexpenInsulin Aspart | 114 | $32,887 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $25,787 |
| RybelsusSemaglutide | 14 | $24,948 |
| Humalog Kwikpen U-200Insulin Lispro | 18 | $23,017 |
| NovologInsulin Aspart | 55 | $21,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,245 | $695,450449 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $732 | $470,235311 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $184 | $116,689101 claims |
| BayerKerendia | $650 | $69,10945 claims |
| Esperion Therapeutics, Inc.Nexletol | $264 | $14,66516 claims |
| AbbVieSynthroid | $73 | $9,05674 claims |
| Cequr CorporationCequr Simplicity | $11,471 | $8,87615 claims |
| Sanofi-aventis U.S. LLCLantus | $199 | $1,89712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $29 | $1,611195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Savannah
- Ismary DecastroSavannah$169K
- Kaveh EhsanipoorSavannah$76K
- Joseph DehavenSavannah$58K
- James StoeverSavannah$11K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.